In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065
- PMID: 10582662
- DOI: 10.1023/a:1006241622639
In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065
Abstract
Cisplatin-induced neuropathy is a major dose-limiting toxicity. Counteraction by amifostine and its metabolite WR1065 may reduce peripheral neurotoxicity in a number of patients. Using the nerve growth factor (NGF)-dependent neurite outgrowth from the PC12 pheochromocytoma cell line as an in vitro assay for neurotoxicity, the protective effects of amifostine and WR1065 against cisplatin action on neurite formation by PC12 cells were studied. Cisplatin in a concentration of 10 microg/ml significantly decreased the percentage of neurite forming cells from 84% to 40%. Amifostine in doses of 0.4 and 0.8 mM proved to protect significantly against the cisplatin-induced decrease in neurite formation, when co-incubated with cisplatin. Also the metabolite WR1065 protected significantly against cisplatin neurotoxicity in a dose of 0.12 mM. Our results show a significant protection by amifostine and its main metabolite WR1065 against cisplatin-induced neurotoxicity using an in vitro model.
Similar articles
-
Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation.Anticancer Res. 2004 Jul-Aug;24(4):2337-41. Anticancer Res. 2004. PMID: 15330181
-
Curcumin reduces cisplatin-induced neurotoxicity in NGF-differentiated PC12 cells.Neurotoxicology. 2013 Jan;34:205-11. doi: 10.1016/j.neuro.2012.09.011. Epub 2012 Oct 2. Neurotoxicology. 2013. PMID: 23036615
-
Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts.Anticancer Res. 1992 Nov-Dec;12(6B):2261-5. Anticancer Res. 1992. PMID: 1338281
-
WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.Cancer Chemother Pharmacol. 1993;33(2):93-106. doi: 10.1007/BF00685326. Cancer Chemother Pharmacol. 1993. PMID: 8261581 Review.
-
The potential of amifostine: from cytoprotectant to therapeutic agent.Haematologica. 1999 Nov;84(11):1035-42. Haematologica. 1999. PMID: 10553165 Review.
Cited by
-
Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group.Support Care Cancer. 2005 Oct;13(10):797-805. doi: 10.1007/s00520-005-0782-y. Epub 2005 Jul 16. Support Care Cancer. 2005. PMID: 16025262 Clinical Trial.
-
Aqueous extract of Lithospermi radix attenuates oxaliplatin-induced neurotoxicity in both in vitro and in vivo models.BMC Complement Altern Med. 2016 Oct 26;16(1):419. doi: 10.1186/s12906-016-1396-2. BMC Complement Altern Med. 2016. PMID: 27782842 Free PMC article.
-
Platinum-induced neurotoxicity and preventive strategies: past, present, and future.Oncologist. 2015 Apr;20(4):411-32. doi: 10.1634/theoncologist.2014-0044. Epub 2015 Mar 12. Oncologist. 2015. PMID: 25765877 Free PMC article. Review.
-
A 3D In Vitro Cortical Tissue Model Based on Dense Collagen to Study the Effects of Gamma Radiation on Neuronal Function.Adv Healthc Mater. 2024 Jan;13(3):e2301123. doi: 10.1002/adhm.202301123. Epub 2023 Nov 16. Adv Healthc Mater. 2024. PMID: 37921265 Free PMC article.
-
Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.Drugs. 2001;61(5):641-84. doi: 10.2165/00003495-200161050-00012. Drugs. 2001. PMID: 11368288 Review.